VOLITIONRX LTD. overview

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update PR Newswire HENDERSON, Nevada, March 31, 2025 Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada , March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal...

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025 PR Newswire HENDERSON, Nev., March 28, 2025 Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized for the early identification of subjects at high risk of cancer HENDERSON, Nev. , March 28, 2025...

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025 PR Newswire HENDERSON, Nev., March 27, 2025 HENDERSON, Nev. , March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on Wednesday, April 9, 2025 , at 10:00 AM ET , featuring Volition's Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter , Chief...

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering PR Newswire HENDERSON, Nev., March 26, 2025 Up to $2.3 million up front with up to an additional $1.1 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev. , March 26, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announces today that it has entered into definitive...

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update PR Newswire HENDERSON, Nev., March 25, 2025 Conference call to take place on Monday, March 31 at 4:30 p.m. U.S Eastern Time HENDERSON, Nev. , March 25, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Monday, March 31 at 4.30 p.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and...

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry PR Newswire HENDERSON, Nev., March 21, 2025 Volition study shows rapid, low-cost, automated Nu.Q® Cancer test accurately detects human cancers at high specificity HENDERSON, Nev. , March 21, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer...

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer PR Newswire HENDERSON, Nev., March 20, 2025 "Lung Cancer: Hope of a Brighter Tomorrow" illustrates how Nu.Q® Cancer Test aims to transform the diagnosis, treatment and monitoring in the $4 billion lung cancer market 1 HENDERSON, Nev. , March 20, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Volition's new lung...

Volition Proudly Sponsors the 44th ISICEM Congress PR Newswire HENDERSON, Nev., March 17, 2025 Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium , from March 18 - 21 HENDERSON, Nev. , March 17, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced its participation at the 44 th Annual ISICEM ("International Symposium on Intensive Care & Emergency...